Future cardiology最新文献_第3页

Carotid artery stenosis: a guide for clinicians. 颈动脉狭窄：临床医生指南。

IF 1.6

Future cardiology Pub Date : 2025-07-22 DOI: 10.1080/14796678.2025.2530909

Kamran Namjouyan, Jonathan A Tangsrivimol, Affan Rizwan, Iqra Riaz, Johao Escobar, Muzamil Khawaja, Hafeez Hassan Virk, Mahboob Alam, Alan Dardik, Chayakrit Krittanawong

引用次数: 0

Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials. 急性失代偿性心力衰竭的血管紧张素-萘普利素抑制：随机对照试验的荟萃分析。

IF 1.6

Future cardiology Pub Date : 2025-07-21 DOI: 10.1080/14796678.2025.2535218

Hosam I Taha, Abdalhakim Shubietah, Bashar M Al Zoubi, Mohamed S Elgendy, Hazem Reyad Mansour, Anas Abdulkader, Abdelrahman M Ghazal, Noura Shamis, Mohamed Abuelazm, Mustafa Turkmani, Robert J Mentz

{"title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure: a meta-analysis of randomized controlled trials.","authors":"Hosam I Taha, Abdalhakim Shubietah, Bashar M Al Zoubi, Mohamed S Elgendy, Hazem Reyad Mansour, Anas Abdulkader, Abdelrahman M Ghazal, Noura Shamis, Mohamed Abuelazm, Mustafa Turkmani, Robert J Mentz","doi":"10.1080/14796678.2025.2535218","DOIUrl":"https://doi.org/10.1080/14796678.2025.2535218","url":null,"abstract":"Background: Angiotensin receptor - neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety after stabilization of acute decompensation (ADHF) remain unclear. This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF.Methods: Meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, WOS, Embase, and CENTRAL up to November 2024. Risk ratios (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) were used.Results: Three RCTs (1,741 patients) were included. ARNI use after ADHF stabilization significantly reduced HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57-0.88; p < 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57-0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64-1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p < 0.0001) and 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI increased symptomatic hypotension risk (RR: 1.33; 95% CI: 1.04-1.71; p = 0.024).Conclusion: initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk.Protocol registration: PROSPERO: CRD42024618027.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-13"},"PeriodicalIF":1.6,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current opinions on the role of apolipoprotein B in the clinical management of cardiovascular risk. 载脂蛋白B在心血管危险临床管理中的作用

IF 1.6

Future cardiology Pub Date : 2025-07-16 DOI: 10.1080/14796678.2025.2535184

Rafael Zubiran, Alan T Remaley

引用次数: 0

Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome. 心肾代谢综合征中非甾体矿皮质激素受体拮抗剂的当代证据。

IF 1.6

Future cardiology Pub Date : 2025-07-08 DOI: 10.1080/14796678.2025.2530842

Tanawat Attachaipanich, Kotchakorn Kaewboot, Suthinee Attachaipanich

{"title":"Contemporary evidence of non-steroidal mineralocorticoid receptor antagonists in cardio-kidney-metabolic syndrome.","authors":"Tanawat Attachaipanich, Kotchakorn Kaewboot, Suthinee Attachaipanich","doi":"10.1080/14796678.2025.2530842","DOIUrl":"https://doi.org/10.1080/14796678.2025.2530842","url":null,"abstract":"Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interaction between cardiovascular (CV) disease, chronic kidney disease (CKD), and metabolic risk factors. Non-steroidal mineralocorticoid receptor antagonists (ns-MRAs) are an emerging therapy showing promise in improving CKM syndrome outcomes. A recent large randomized trial, the FINEARTS-HF study, demonstrated a 16% reduction in the composite endpoint of worsening heart failure (HF) and CV death in patients with mildly reduced and preserved ejection fraction after a median 32-month follow-up. Additionally, two pivotal randomized studies demonstrated the efficacy of finerenone in CKD with diabetes patients. The FIDELIO-DKD trial showed a reduction in the renal composite outcome, including kidney failure and related death, over 2.6 years. Similarly, the FIGARO-DKD trial demonstrated a reduction in composite CV outcomes, including CV death, myocardial infarction, stroke, or HF hospitalization, after a median follow-up of 3.4 years. Evidence from in vitro and in vivo studies suggests that finerenone attenuates cardiac and kidney injury by reducing fibrosis, apoptotic cell death, oxidative stress, and endothelial dysfunction. Despite these advances, further research is necessary to evaluate the efficacy of ns-MRAs in specific CKM subpopulations, including HF with reduced ejection fraction and CKD without diabetes, to expand their indications and improve outcomes for CKM syndrome patients.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-15"},"PeriodicalIF":1.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac MRI: a pivotal tool for the management of cardiomyopathy. 心脏MRI：心肌病治疗的关键工具。

IF 1.6

Future cardiology Pub Date : 2025-07-03 DOI: 10.1080/14796678.2025.2529692

Edoardo Conte, Susanna Landi, Daniele Andreini

引用次数: 0

Direct oral anticoagulants in stroke prevention of atrial fibrillation patients: can we rely on them in all clinical scenarios? 直接口服抗凝剂预防房颤患者脑卒中：我们可以在所有临床情况下依赖它们吗？

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-05-15 DOI: 10.1080/14796678.2025.2506915

Mattia Galli, Dominick J Angiolillo

引用次数: 0

The challenges in improving myocardial infarction outcomes and the year 2024 in a nutshell. 改善心肌梗死预后的挑战和2024年的概述。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1080/14796678.2025.2503692

Muhammad Adnan Zaman

引用次数: 0

Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH). 简单的语言总结：口服曲前列地尼（奥伦特仑）治疗肺动脉高压（PAH）。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-17 DOI: 10.1080/14796678.2025.2507466

Brittany N J Davis, Tara Suplicki, Natalie Patzlaff, James White

引用次数: 0

Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. 西马鲁肽：治疗心血管-肾-代谢综合征的关键药物。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-03 DOI: 10.1080/14796678.2025.2511412

Richard J MacIsaac

{"title":"Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.","authors":"Richard J MacIsaac","doi":"10.1080/14796678.2025.2511412","DOIUrl":"10.1080/14796678.2025.2511412","url":null,"abstract":"Recent trials underscore the cardiovascular (CV), renal, and metabolic benefits of semaglutide in individuals with and without type 2 diabetes (T2D). In T2D, semaglutide enhances glycemic control, reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression. The SUSTAIN-6 trial demonstrated a 26% MACE reduction (HR 0.74; 95% CI: 0.58-0.95; p = 0.02) in high CV-risk patients with T2D using semaglutide (0.5 or 1.0 mg weekly). Similarly, the FLOW trial showed a 24% reduction in major kidney disease events (HR 0.76; 95% CI: 0.66-0.88; p = 0.002) with weekly 1.0 mg semaglutide in individuals with T2D with CKD. Beyond T2D, the SELECT trial highlighted semaglutide's efficacy in reducing MACE by 20% (HR 0.80; 95% CI: 0.72-0.90; p < 0.001) and slowing kidney function loss in overweight or obese individuals with preexisting CV disease using 2.4 mg weekly. Additionally, semaglutide alleviates heart failure symptoms and reduces hospitalizations in obese individuals regardless of T2D status. These findings underscore semaglutide's role in improving kidney, CV, and survival outcomes among high-risk patients. This review highlights the cardio-kidney-metabolic benefits of semaglutide in individuals with and without T2D to inform cardiologists about its potential to enhance patient care.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"663-683"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stenting strategy and imaging use in left main percutaneous coronary intervention: insights from a 15-year registry. 左主干经皮冠状动脉介入治疗支架置入策略和影像学应用：来自15年登记的见解。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1080/14796678.2025.2511416

Judit Andreka, Fazila-Tun-Nesa Malik, Mariam Khandaker, Kalim Uddin, Abdul Kayum, Anass Maaroufi, Dan Prunea, Zoltan Ruzsa, Gabor G Toth

{"title":"Stenting strategy and imaging use in left main percutaneous coronary intervention: insights from a 15-year registry.","authors":"Judit Andreka, Fazila-Tun-Nesa Malik, Mariam Khandaker, Kalim Uddin, Abdul Kayum, Anass Maaroufi, Dan Prunea, Zoltan Ruzsa, Gabor G Toth","doi":"10.1080/14796678.2025.2511416","DOIUrl":"10.1080/14796678.2025.2511416","url":null,"abstract":"Background: Left main (LM) percutaneous coronary intervention (PCI) remains a major interventional challenge, with outcomes influenced by various patient- and procedure-related factors.Objectives: To analyze procedural characteristics and outcomes of patients who underwent LM PCI over a 15-year period in a single center.Methods: We retrospectively analyzed data from all consecutive patients who underwent LM PCI between 2006 and 2022. Procedural details, with a focus on stenting technique, were collected. Primary outcome was all-cause mortality at 1 year.Results: In total 3494 patients were included. The majority (67%) presented with chronic coronary syndrome. Seventy-seven percent of all patients (n = 2690) underwent PCI by single stent (SS) strategy and 23% (n = 804) by double stent (DS) strategy. One-year mortality was significantly lower in SS cases compared to DS (3.5% vs. 5.1%, HR 0.64, 95% CI 0.43-0.96). Intravascular imaging was used in 17% of the cases but showed no significant difference in one-year mortality compared to angio-guided PCI (4.8% vs. 3.7%; HR 1.11, 95% CI 0.71-1.73).Conclusions: In real-world LM PCI practice, patients for whom a provisional single-stent strategy was feasible had better outcomes than those requiring a double-stent approach.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"693-700"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0